Icu Medical signals 2026 results toward high end of $415M-$435M EBITDA and $8.60-$9 EPS range as logistics consolidation normalizes (NASDAQ:ICUI)
ICU Medical (ICUI) reported Q3 2026 revenue of $556M, up 5% organically. CEO Vivek Jain expects 2026 EBITDA and EPS to be near the high end of the $415M-$435M and $8.60-$9 ranges, respectively, as logistics normalize. Adjusted gross margins were 42%.
How this was made
The 30-second read
Why it matters
The high‑end guidance signals robust demand and operational efficiency, likely prompting buying interest.
Market read
First disclosure of 2026 guidance for ICU Medical, a material catalyst for the stock.
What to watch
Potential supply‑chain constraints or upcoming regulatory changes could temper the positive impact.
Background
ICU Medical's earnings call provided Q3 revenue and margin figures and forward guidance for 2026.
Ticker impact
ICU Medical disclosed Q3 2026 revenue of $556M and guidance toward the high end of $415M-$435M EBITDA and $8.60-$9 EPS.
potential upside as market prices in the strong guidance
The disclosed guidance exceeds prior expectations and is the first report of these numbers, giving traders a fresh catalyst.
Market effects
Positive outlook may lift other medical device peers.
U.S. healthcare sector could see modest gains.
Limited to U.S. and global med‑tech investors.
Counterpoint
If the market had already priced in strong growth, the guidance may be already baked in, limiting upside.
Key entities
- ExecutiveVivek Jain
CEO & Chairman of ICU Medical who delivered the guidance.
